CA2961041C - Lipase variants for pharmaceutical use - Google Patents
Lipase variants for pharmaceutical use Download PDFInfo
- Publication number
- CA2961041C CA2961041C CA2961041A CA2961041A CA2961041C CA 2961041 C CA2961041 C CA 2961041C CA 2961041 A CA2961041 A CA 2961041A CA 2961041 A CA2961041 A CA 2961041A CA 2961041 C CA2961041 C CA 2961041C
- Authority
- CA
- Canada
- Prior art keywords
- lipase
- seq
- enzyme
- amino acids
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090001060 Lipase Proteins 0.000 title claims abstract description 376
- 102000004882 Lipase Human genes 0.000 title claims abstract description 372
- 239000004367 Lipase Substances 0.000 title claims abstract description 369
- 235000019421 lipase Nutrition 0.000 title claims abstract description 369
- 150000001413 amino acids Chemical class 0.000 claims abstract description 101
- 102220479102 CD59 glycoprotein_N33Q_mutation Human genes 0.000 claims description 988
- 102220598657 5-hydroxytryptamine receptor 1E_D27R_mutation Human genes 0.000 claims description 159
- 238000006467 substitution reaction Methods 0.000 claims description 102
- 102220052839 rs73113102 Human genes 0.000 claims description 60
- 102200108133 rs201753350 Human genes 0.000 claims description 49
- 102220056648 rs730881059 Human genes 0.000 claims description 26
- 102220105300 rs879254420 Human genes 0.000 claims description 25
- 235000019626 lipase activity Nutrition 0.000 claims description 17
- 102220105121 rs150066950 Human genes 0.000 claims description 17
- 102220487741 Protein eyes shut homolog_D27N_mutation Human genes 0.000 claims description 14
- 102220083998 rs551990619 Human genes 0.000 claims description 14
- 102220020884 rs80356880 Human genes 0.000 claims description 11
- 102220360655 c.170A>G Human genes 0.000 claims description 7
- 102200006121 rs1060501260 Human genes 0.000 claims description 7
- 102220593541 PMS1 protein homolog 1_N11D_mutation Human genes 0.000 claims description 4
- 102220125026 rs886043836 Human genes 0.000 claims description 4
- 102220010822 rs397514616 Human genes 0.000 claims 40
- 102220059322 rs786203566 Human genes 0.000 claims 4
- 102200163576 rs28929478 Human genes 0.000 claims 1
- 102220084740 rs767734253 Human genes 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract description 90
- 230000000694 effects Effects 0.000 abstract description 58
- 108091005804 Peptidases Proteins 0.000 abstract description 52
- 239000004365 Protease Substances 0.000 abstract description 52
- 108010065511 Amylases Proteins 0.000 abstract description 46
- 102000013142 Amylases Human genes 0.000 abstract description 46
- 235000019418 amylase Nutrition 0.000 abstract description 45
- 239000004382 Amylase Substances 0.000 abstract description 42
- 238000000034 method Methods 0.000 abstract description 36
- 239000003833 bile salt Substances 0.000 abstract description 35
- 102000057297 Pepsin A Human genes 0.000 abstract description 32
- 108090000284 Pepsin A Proteins 0.000 abstract description 32
- 229940111202 pepsin Drugs 0.000 abstract description 32
- 230000029087 digestion Effects 0.000 abstract description 31
- 238000000338 in vitro Methods 0.000 abstract description 27
- 229940093761 bile salts Drugs 0.000 abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 16
- 208000035467 Pancreatic insufficiency Diseases 0.000 abstract description 13
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 12
- 208000035475 disorder Diseases 0.000 abstract description 10
- 241000223258 Thermomyces lanuginosus Species 0.000 abstract description 9
- 230000001079 digestive effect Effects 0.000 abstract description 8
- 201000003883 Cystic fibrosis Diseases 0.000 abstract description 7
- 206010033645 Pancreatitis Diseases 0.000 abstract description 6
- 238000006731 degradation reaction Methods 0.000 abstract description 5
- 230000007935 neutral effect Effects 0.000 abstract description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 102220097791 rs201753350 Human genes 0.000 description 354
- 229940040461 lipase Drugs 0.000 description 283
- 102000004190 Enzymes Human genes 0.000 description 120
- 108090000790 Enzymes Proteins 0.000 description 120
- 229940088598 enzyme Drugs 0.000 description 111
- 235000001014 amino acid Nutrition 0.000 description 101
- 229940024606 amino acid Drugs 0.000 description 99
- 102220104423 rs63749907 Human genes 0.000 description 89
- 102220606460 C-reactive protein_G163V_mutation Human genes 0.000 description 60
- 102000035195 Peptidases Human genes 0.000 description 51
- 235000019419 proteases Nutrition 0.000 description 41
- 102220254290 rs1553156175 Human genes 0.000 description 35
- 102220257095 rs587779102 Human genes 0.000 description 32
- 239000000203 mixture Substances 0.000 description 30
- 229920001223 polyethylene glycol Polymers 0.000 description 29
- 239000002202 Polyethylene glycol Substances 0.000 description 27
- 230000006872 improvement Effects 0.000 description 27
- 125000003275 alpha amino acid group Chemical group 0.000 description 24
- 235000005911 diet Nutrition 0.000 description 24
- 230000037213 diet Effects 0.000 description 24
- 229910052700 potassium Inorganic materials 0.000 description 23
- 239000000523 sample Substances 0.000 description 20
- 102220021416 rs80357110 Human genes 0.000 description 19
- 102220057725 rs374836770 Human genes 0.000 description 18
- 229920004890 Triton X-100 Polymers 0.000 description 16
- 102220536108 Serine/threonine-protein kinase OSR1_K46M_mutation Human genes 0.000 description 15
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 15
- 102200121669 rs104894915 Human genes 0.000 description 15
- 102220276634 rs1553131563 Human genes 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 102220412429 c.297A>C Human genes 0.000 description 14
- 235000010980 cellulose Nutrition 0.000 description 14
- 229920002678 cellulose Polymers 0.000 description 14
- 239000001913 cellulose Substances 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 14
- 102220475917 Oligophrenin-1_G91V_mutation Human genes 0.000 description 13
- 230000002496 gastric effect Effects 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 239000000758 substrate Substances 0.000 description 13
- 229910052717 sulfur Inorganic materials 0.000 description 13
- 238000012217 deletion Methods 0.000 description 12
- 230000037430 deletion Effects 0.000 description 12
- -1 Japan Substances 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 239000002775 capsule Substances 0.000 description 10
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 10
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 10
- 235000021588 free fatty acids Nutrition 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 10
- 239000008188 pellet Substances 0.000 description 10
- 229910052698 phosphorus Inorganic materials 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 108010019160 Pancreatin Proteins 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 235000019197 fats Nutrition 0.000 description 9
- 229940055695 pancreatin Drugs 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 102200110982 rs28931568 Human genes 0.000 description 9
- 241000282898 Sus scrofa Species 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102220041676 rs587779102 Human genes 0.000 description 8
- 102220330013 rs78488639 Human genes 0.000 description 8
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 7
- 102220564804 Killer cell immunoglobulin-like receptor 2DL2_N73D_mutation Human genes 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 108010064785 Phospholipases Proteins 0.000 description 7
- 102000015439 Phospholipases Human genes 0.000 description 7
- 102220593678 Stromal interaction molecule 1_E87Q_mutation Human genes 0.000 description 7
- 230000004075 alteration Effects 0.000 description 7
- 235000008504 concentrate Nutrition 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 210000000496 pancreas Anatomy 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 102220198277 rs1057519874 Human genes 0.000 description 7
- 102220204637 rs137852883 Human genes 0.000 description 7
- 102220104592 rs879254078 Human genes 0.000 description 7
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- 102100023105 Sialin Human genes 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 150000005690 diesters Chemical class 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 230000002538 fungal effect Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 6
- 102200080817 rs104894869 Human genes 0.000 description 6
- 102220082775 rs144148008 Human genes 0.000 description 6
- 102220245301 rs1555596673 Human genes 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 238000004448 titration Methods 0.000 description 6
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 5
- 241000228212 Aspergillus Species 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- 102220552927 Fidgetin-like protein 1_G163H_mutation Human genes 0.000 description 5
- 241000223198 Humicola Species 0.000 description 5
- 102220536901 PRKC apoptosis WT1 regulator protein_L69I_mutation Human genes 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 229960001230 asparagine Drugs 0.000 description 5
- 235000009582 asparagine Nutrition 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000001110 calcium chloride Substances 0.000 description 5
- 229910001628 calcium chloride Inorganic materials 0.000 description 5
- 235000011148 calcium chloride Nutrition 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 229920000620 organic polymer Polymers 0.000 description 5
- 102200027496 rs63751429 Human genes 0.000 description 5
- 102200101939 rs72554338 Human genes 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 102220524143 Cadherin-24_N26I_mutation Human genes 0.000 description 4
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 4
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 4
- 102100031415 Hepatic triacylglycerol lipase Human genes 0.000 description 4
- 102220515651 Insulin-like growth factor I_R84E_mutation Human genes 0.000 description 4
- 239000005639 Lauric acid Substances 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- 235000021314 Palmitic acid Nutrition 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- 102220600976 Syndecan-4_N26A_mutation Human genes 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 230000008033 biological extinction Effects 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 235000019621 digestibility Nutrition 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- 229960002446 octanoic acid Drugs 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000011533 pre-incubation Methods 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 102200131348 rs57983345 Human genes 0.000 description 4
- 102220184188 rs758665573 Human genes 0.000 description 4
- 102220028139 rs80357084 Human genes 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000008117 stearic acid Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 241000981399 Aspergillus melleus Species 0.000 description 3
- 240000006439 Aspergillus oryzae Species 0.000 description 3
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 102220568523 Clustered mitochondria protein homolog_E99S_mutation Human genes 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 102100037611 Lysophospholipase Human genes 0.000 description 3
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102220517768 Methyl-CpG-binding domain protein 3-like 2B_D27Y_mutation Human genes 0.000 description 3
- 235000021360 Myristic acid Nutrition 0.000 description 3
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 3
- 239000004111 Potassium silicate Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000282849 Ruminantia Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 102220616017 Sterile alpha motif domain-containing protein 5_D96Y_mutation Human genes 0.000 description 3
- 102220496421 Zinc finger CCHC domain-containing protein 24_E43V_mutation Human genes 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 229940025131 amylases Drugs 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 3
- 229940062190 pancreas extract Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
- 229920001592 potato starch Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 102220277043 rs1553408229 Human genes 0.000 description 3
- 102220271537 rs200383861 Human genes 0.000 description 3
- 102220041065 rs200979664 Human genes 0.000 description 3
- 102220045389 rs587782063 Human genes 0.000 description 3
- 102200116704 rs77587352 Human genes 0.000 description 3
- 102200158370 rs868333 Human genes 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- DRCWOKJLSQUJPZ-DZGCQCFKSA-N (4ar,9as)-n-ethyl-1,4,9,9a-tetrahydrofluoren-4a-amine Chemical compound C1C2=CC=CC=C2[C@]2(NCC)[C@H]1CC=CC2 DRCWOKJLSQUJPZ-DZGCQCFKSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 102100035687 Bile salt-activated lipase Human genes 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 102220644676 Galectin-related protein_D96L_mutation Human genes 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 101001008429 Homo sapiens Nucleobindin-2 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102220508063 Mitochondrial folate transporter/carrier_G91R_mutation Human genes 0.000 description 2
- 241000203622 Nocardiopsis Species 0.000 description 2
- 102100027441 Nucleobindin-2 Human genes 0.000 description 2
- 102000019280 Pancreatic lipases Human genes 0.000 description 2
- 108050006759 Pancreatic lipases Proteins 0.000 description 2
- 102220474144 Phosphatidylcholine-sterol acyltransferase_T37M_mutation Human genes 0.000 description 2
- 102100035200 Phospholipase A and acyltransferase 4 Human genes 0.000 description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 241000235527 Rhizopus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 241000228341 Talaromyces Species 0.000 description 2
- 241000223257 Thermomyces Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 239000001166 ammonium sulphate Substances 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 102220363768 c.76A>C Human genes 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000006194 liquid suspension Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 229940116369 pancreatic lipase Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 2
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 102200161847 rs104894126 Human genes 0.000 description 2
- 102200158812 rs104894225 Human genes 0.000 description 2
- 102220312400 rs1555802310 Human genes 0.000 description 2
- 102200028671 rs3765620 Human genes 0.000 description 2
- 102200027488 rs63749907 Human genes 0.000 description 2
- 102200058234 rs80338731 Human genes 0.000 description 2
- 102220087418 rs864622444 Human genes 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000011218 seed culture Methods 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 108010079522 solysime Proteins 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- GGIDEJQGAZSTES-UHFFFAOYSA-N (4-nitrophenyl) octanoate Chemical compound CCCCCCCC(=O)OC1=CC=C([N+]([O-])=O)C=C1 GGIDEJQGAZSTES-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- HBOQXIRUPVQLKX-BBWANDEASA-N 1,2,3-trilinoleoylglycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)COC(=O)CCCCCCC\C=C/C\C=C/CCCCC HBOQXIRUPVQLKX-BBWANDEASA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 102220473558 ADP-ribosylation factor-like protein 2-binding protein_E56A_mutation Human genes 0.000 description 1
- 241001019659 Acremonium <Plectosphaerellaceae> Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000235349 Ascomycota Species 0.000 description 1
- 101001065065 Aspergillus awamori Feruloyl esterase A Proteins 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 102220560906 Ataxin-2_N73Y_mutation Human genes 0.000 description 1
- 241000223651 Aureobasidium Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 108091005658 Basic proteases Proteins 0.000 description 1
- 101710130200 Bile salt-activated lipase Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108010051152 Carboxylesterase Proteins 0.000 description 1
- 102000013392 Carboxylesterase Human genes 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 241000252210 Cyprinidae Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000221207 Filobasidium Species 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 241000171741 Humicola fuscoatra Species 0.000 description 1
- 241000223199 Humicola grisea Species 0.000 description 1
- 241001480714 Humicola insolens Species 0.000 description 1
- 241001350650 Humicola lutea Species 0.000 description 1
- 241000259838 Humicola nigrescens Species 0.000 description 1
- 241001373560 Humicola sp. Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102220642119 Lipoma-preferred partner_D96R_mutation Human genes 0.000 description 1
- 108020002496 Lysophospholipase Proteins 0.000 description 1
- 241001344133 Magnaporthe Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241000226677 Myceliophthora Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 102220526321 NHP2-like protein 1_G38K_mutation Human genes 0.000 description 1
- 241000233892 Neocallimastix Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 241001221335 Nocardiopsis sp. Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 102100026367 Pancreatic alpha-amylase Human genes 0.000 description 1
- 102100033357 Pancreatic lipase-related protein 2 Human genes 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 241000235379 Piromyces Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 239000004353 Polyethylene glycol 8000 Substances 0.000 description 1
- 241000030452 Rasamsonia byssochlamydoides Species 0.000 description 1
- 241000959173 Rasamsonia emersonii Species 0.000 description 1
- 241000303962 Rhizopus delemar Species 0.000 description 1
- 241000588264 Rhizopus javanicus Species 0.000 description 1
- 240000005384 Rhizopus oryzae Species 0.000 description 1
- 235000013752 Rhizopus oryzae Nutrition 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 241000222480 Schizophyllum Species 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 201000004283 Shwachman-Diamond syndrome Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000228178 Thermoascus Species 0.000 description 1
- 241001261109 Thermomyces ibadanensis Species 0.000 description 1
- 241000650705 Thermomyces verrucosus Species 0.000 description 1
- 241001494489 Thielavia Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241000276707 Tilapia Species 0.000 description 1
- 241001149964 Tolypocladium Species 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 101150049278 US20 gene Proteins 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 108010058834 acylcarnitine hydrolase Proteins 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000006136 alcoholysis reaction Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000001508 asparagines Chemical class 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 108010087173 bile salt-stimulated lipase Proteins 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229940082483 carnauba wax Drugs 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 241001233037 catfish Species 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 210000001953 common bile duct Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- XCSQXCKDEVRTHN-UHFFFAOYSA-N cyclohexa-1,4-diene-1-carboxylic acid Chemical compound OC(=O)C1=CCC=CC1 XCSQXCKDEVRTHN-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000020979 dietary recommendations Nutrition 0.000 description 1
- 235000020930 dietary requirements Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 108091007735 digestive proteases Proteins 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000225 effect on diabetes Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 238000002641 enzyme replacement therapy Methods 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000013110 gastrectomy Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000001279 glycosylating effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 229920013746 hydrophilic polyethylene oxide Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- HBOQXIRUPVQLKX-UHFFFAOYSA-N linoleic acid triglyceride Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC HBOQXIRUPVQLKX-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 230000020958 lipid digestion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229920003087 methylethyl cellulose Polymers 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 108010020132 microbial serine proteinases Proteins 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 244000309715 mini pig Species 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- VYGYNVZNSSTDLJ-HKCOAVLJSA-N monorden Natural products CC1CC2OC2C=C/C=C/C(=O)CC3C(C(=CC(=C3Cl)O)O)C(=O)O1 VYGYNVZNSSTDLJ-HKCOAVLJSA-N 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 108090000021 oryzin Proteins 0.000 description 1
- LVZSQWIWCANHPF-UHFFFAOYSA-N p-nitrophenyl palmitate Chemical group CCCCCCCCCCCCCCCC(=O)OC1=CC=C([N+]([O-])=O)C=C1 LVZSQWIWCANHPF-UHFFFAOYSA-N 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229940113125 polyethylene glycol 3000 Drugs 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229940085678 polyethylene glycol 8000 Drugs 0.000 description 1
- 235000019446 polyethylene glycol 8000 Nutrition 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 102200097285 rs199473487 Human genes 0.000 description 1
- 102200006128 rs559848002 Human genes 0.000 description 1
- 102220229111 rs759454598 Human genes 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229940081852 trilinolein Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Detergent Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3081308A CA3081308C (en) | 2006-12-21 | 2007-12-12 | Lipase variants for pharmaceutical use |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87119606P | 2006-12-21 | 2006-12-21 | |
| US60/871,196 | 2006-12-21 | ||
| CA2670643A CA2670643C (en) | 2006-12-21 | 2007-12-12 | Lipase variants for pharmaceutical use |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2670643A Division CA2670643C (en) | 2006-12-21 | 2007-12-12 | Lipase variants for pharmaceutical use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3081308A Division CA3081308C (en) | 2006-12-21 | 2007-12-12 | Lipase variants for pharmaceutical use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2961041A1 CA2961041A1 (en) | 2008-07-03 |
| CA2961041C true CA2961041C (en) | 2020-07-14 |
Family
ID=38043020
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2961041A Active CA2961041C (en) | 2006-12-21 | 2007-12-12 | Lipase variants for pharmaceutical use |
| CA2670643A Active CA2670643C (en) | 2006-12-21 | 2007-12-12 | Lipase variants for pharmaceutical use |
| CA3081308A Active CA3081308C (en) | 2006-12-21 | 2007-12-12 | Lipase variants for pharmaceutical use |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2670643A Active CA2670643C (en) | 2006-12-21 | 2007-12-12 | Lipase variants for pharmaceutical use |
| CA3081308A Active CA3081308C (en) | 2006-12-21 | 2007-12-12 | Lipase variants for pharmaceutical use |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US8273348B2 (enExample) |
| EP (6) | EP2455461B1 (enExample) |
| JP (1) | JP5406040B2 (enExample) |
| KR (1) | KR20090101930A (enExample) |
| CN (2) | CN105112386A (enExample) |
| AR (1) | AR064494A1 (enExample) |
| AU (1) | AU2007337150A1 (enExample) |
| BR (1) | BRPI0721103A2 (enExample) |
| CA (3) | CA2961041C (enExample) |
| IL (1) | IL198893A0 (enExample) |
| MX (1) | MX2009006597A (enExample) |
| NO (1) | NO20092729L (enExample) |
| RU (1) | RU2009128067A (enExample) |
| TW (1) | TW200829698A (enExample) |
| WO (1) | WO2008079685A2 (enExample) |
| ZA (1) | ZA200903598B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5032300B2 (ja) | 2004-03-22 | 2012-09-26 | アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 界面活性剤を含有している、リパーゼを含有する生成物の、とりわけパンクレアチンの経口医薬組成物 |
| EP2278002B1 (en) | 2005-07-29 | 2017-07-12 | Abbott Laboratories GmbH | Pancreatin with reduced viral content |
| US9198871B2 (en) | 2005-08-15 | 2015-12-01 | Abbott Products Gmbh | Delayed release pancreatin compositions |
| US11266607B2 (en) | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
| US10072256B2 (en) | 2006-05-22 | 2018-09-11 | Abbott Products Gmbh | Process for separating and determining the viral load in a pancreatin sample |
| WO2008079685A2 (en) * | 2006-12-21 | 2008-07-03 | Novozymes A/S | Lipase variants for pharmaceutical use |
| JP2011513539A (ja) * | 2008-02-29 | 2011-04-28 | ザ プロクター アンド ギャンブル カンパニー | リパーゼを含む洗剤組成物 |
| MX2010009464A (es) | 2008-02-29 | 2010-09-22 | Dsm Ip Assets Bv | Lipasas con alta especificidad hacia acidos grasos de cadena corta y usos de las mismas. |
| EP2250258B1 (en) * | 2008-02-29 | 2017-01-04 | Novozymes A/S | Lipolytic enzyme variant with improved stability and polynucleotides encoding same |
| CA2782613C (en) | 2009-12-09 | 2016-08-23 | The Procter & Gamble Company | Fabric and home care products |
| US20140147895A1 (en) | 2011-07-22 | 2014-05-29 | Novozymes A/S | Processes for Pretreating Cellulosic Material and Improving Hydrolysis Thereof |
| US8268305B1 (en) | 2011-09-23 | 2012-09-18 | Bio-Cat, Inc. | Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase |
| ES2680145T3 (es) * | 2011-12-29 | 2018-09-04 | Novozymes A/S | Composiciones detergentes con variantes de lipasa |
| US9394530B2 (en) * | 2012-02-03 | 2016-07-19 | Novozymes A/S | Lipase variants and polynucleotides encoding same |
| WO2013149858A1 (en) | 2012-04-02 | 2013-10-10 | Novozymes A/S | Lipase variants and polynucleotides encoding same |
| CA2887898A1 (en) * | 2012-10-12 | 2014-04-17 | Danisco Us Inc. | Compositions and methods comprising a lipolytic enzyme variant |
| CN115521831A (zh) * | 2013-05-14 | 2022-12-27 | 诺维信公司 | 洗涤剂组合物 |
| ES2956266T3 (es) * | 2013-07-19 | 2023-12-18 | Danisco Us Inc | Composiciones y procedimientos que comprenden una variante de enzima lipolítica |
| EP3221447A1 (en) * | 2014-11-20 | 2017-09-27 | Novozymes A/S | Alicyclobacillus variants and polynucleotides encoding same |
| US10457921B2 (en) | 2014-12-05 | 2019-10-29 | Novozymes A/S | Lipase variants and polynucleotides encoding same |
| MX382218B (es) * | 2014-12-09 | 2025-03-13 | Novozymes As | Variantes de lipasa y polinucleotidos que las codifican. |
| EP3280818A2 (en) | 2015-04-07 | 2018-02-14 | Novozymes A/S | Methods for selecting enzymes having lipase activity |
| EP3317407B1 (en) * | 2015-07-01 | 2021-05-19 | Novozymes A/S | Methods of reducing odor |
| US10760037B2 (en) * | 2015-07-03 | 2020-09-01 | Novozymes A/S | Sulfite compositions |
| US11326152B2 (en) | 2016-07-18 | 2022-05-10 | Novozymes A/S | Lipase variants, polynucleotides encoding same and the use thereof |
| JP7081767B2 (ja) * | 2017-01-30 | 2022-06-07 | 学校法人日本医科大学 | アデノ随伴ウイルス（ａａｖ）キャプシドタンパク質の変異体 |
| MX2020003779A (es) * | 2017-09-27 | 2020-08-03 | Procter & Gamble | Composiciones detergentes que comprenden lipasas. |
| JP7317811B2 (ja) * | 2017-09-27 | 2023-07-31 | ノボザイムス アクティーゼルスカブ | リパーゼ変異体及びかかるリパーゼ変異体を含むマイクロカプセル組成物 |
| WO2019154952A1 (en) * | 2018-02-08 | 2019-08-15 | Novozymes A/S | Lipase variants and compositions thereof |
| WO2020037100A1 (en) * | 2018-08-16 | 2020-02-20 | Isolere Bio, Inc. | Genetically encoded polypeptide for affinity capture and purification of biologics |
| CN111334369B (zh) * | 2020-03-11 | 2022-10-21 | 陕西科技大学 | 一种酶法制备卵磷脂型pufa的方法 |
| US12467042B2 (en) * | 2020-06-24 | 2025-11-11 | Dermapharm Aktiengesellschaft | Lipase enzyme |
| EP4237552A2 (en) * | 2020-10-29 | 2023-09-06 | Novozymes A/S | Lipase variants and compositions comprising such lipase variants |
| CN113846074B (zh) * | 2021-10-20 | 2022-10-21 | 南京林业大学 | 一种疏棉状嗜热丝孢菌脂肪酶突变体g91c及其应用 |
| AU2023272468A1 (en) | 2022-05-14 | 2024-11-14 | Novonesis Plant Biosolutions A/S | Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections |
| CN119522274A (zh) * | 2022-06-24 | 2025-02-25 | 诺维信公司 | 脂肪酶变体和包含这样的脂肪酶变体的组合物 |
| CN120082537A (zh) * | 2023-12-01 | 2025-06-03 | 青岛蔚蓝生物集团有限公司 | 一种脂肪酶突变体 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK173590D0 (da) | 1990-06-06 | 1990-07-19 | Novo Nordisk As | Rekombinante terapeutiske lipaser |
| DK46693D0 (enExample) | 1993-04-23 | 1993-04-23 | Novo Nordisk As | |
| US5869438A (en) | 1990-09-13 | 1999-02-09 | Novo Nordisk A/S | Lipase variants |
| JP3469234B2 (ja) * | 1990-09-13 | 2003-11-25 | ノボザイムス アクティーゼルスカブ | リパーゼ変異体 |
| DE69130113T2 (de) | 1990-12-05 | 1999-05-12 | Novo Nordisk A/S, Bagsvaerd | Proteine mit geänderten epitopen und verfahren zur deren herstellung |
| ATE169678T1 (de) | 1991-05-01 | 1998-08-15 | Novo Nordisk As | Stabilisierte enzyme |
| DK39693D0 (da) | 1993-04-02 | 1993-04-02 | Novo Nordisk As | Enzym |
| BR9407752A (pt) | 1993-10-04 | 1997-03-04 | Novo Nordisk As | Preparaçao de enzima aditivo detergente composiçao detergente processo para o tratamento de fibras lignocelulósicas |
| AU1806795A (en) | 1994-02-22 | 1995-09-04 | Novo Nordisk A/S | A method of preparing a variant of a lipolytic enzyme |
| JPH10509324A (ja) | 1994-11-24 | 1998-09-14 | ノボ ノルディスク アクティーゼルスカブ | 抑制されたアレルゲン性を有するポリペプチドの製造のための方法 |
| AU697440B2 (en) | 1994-12-07 | 1998-10-08 | Novozymes A/S | Polypeptide with reduced allergenicity |
| CA2209617C (en) | 1995-01-26 | 2002-05-28 | Novo Nordisk A/S | Animal feed additives comprising xylanase |
| WO1997004079A1 (en) | 1995-07-14 | 1997-02-06 | Novo Nordisk A/S | A modified enzyme with lipolytic activity |
| US6495357B1 (en) * | 1995-07-14 | 2002-12-17 | Novozyme A/S | Lipolytic enzymes |
| CN1192780B (zh) | 1995-08-11 | 2010-08-04 | 诺沃奇梅兹有限公司 | 新的脂解酶 |
| JP2002510963A (ja) | 1997-01-10 | 2002-04-09 | ノボザイムス アクティーゼルスカブ | スキンケア用酵素修飾体 |
| JP2001511162A (ja) | 1997-02-06 | 2001-08-07 | ノボ ノルディスク アクティーゼルスカブ | 付加され、そして／又は除去された付着基を有するポリペプチド−ポリマー結合体 |
| JP2002516615A (ja) | 1997-06-25 | 2002-06-04 | ノボザイムス アクティーゼルスカブ | 変性ポリペプチド |
| ATE328070T1 (de) * | 1998-02-17 | 2006-06-15 | Novozymes As | Lipasevariante |
| AU3247699A (en) | 1998-02-17 | 1999-09-06 | Novo Nordisk A/S | Lipase variant |
| WO2000022103A1 (en) | 1998-10-13 | 2000-04-20 | Novozymes A/S | A modified polypeptide with reduced immune response |
| DE69938435D1 (de) | 1998-10-30 | 2008-05-08 | Novozymes As | Niedrigallergene Proteinvarianten |
| CA2348822A1 (en) | 1998-10-30 | 2000-05-11 | Novozymes A/S | Glycosylated proteins having reduced allergenicity |
| EP1131416B1 (en) | 1998-11-27 | 2009-09-02 | Novozymes A/S | Lipolytic enzyme variants |
| US7312062B2 (en) * | 1998-11-27 | 2007-12-25 | Novozymes A/S | Lipolytic enzyme variants |
| TR200102784T2 (tr) | 1999-03-17 | 2002-04-22 | Solvay Pharmaceuticals Gmbh | Diyabet tedavisi için ilaç |
| EP1171581A1 (en) * | 1999-03-31 | 2002-01-16 | Novozymes A/S | Lipase variant |
| EP2278000A1 (en) * | 1999-03-31 | 2011-01-26 | Novozymes A/S | Lipase variant |
| WO2001058276A2 (en) | 2000-02-08 | 2001-08-16 | F Hoffmann-La Roche Ag | Use of acid-stable proteases in animal feed |
| WO2001083761A1 (en) | 2000-04-28 | 2001-11-08 | Novozymes A/S | Laccase mutants |
| DE60231700D1 (de) * | 2001-01-10 | 2009-05-07 | Novozymes As | Variante eines lipolytischen enzyms |
| AR032392A1 (es) | 2001-01-19 | 2003-11-05 | Solvay Pharm Gmbh | Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado. |
| CN1491278A (zh) | 2001-02-07 | 2004-04-21 | ŵά�Ź�˾ | 脂酶变体 |
| EP1468084A1 (en) * | 2002-01-16 | 2004-10-20 | Novozymes A/S | Lipolytic enzyme variants and method for their production |
| JP2007506405A (ja) | 2003-02-06 | 2007-03-22 | ノボザイムス アクティーゼルスカブ | 糸状菌におけるヒトｈ鎖抗体の発現 |
| EP2270139B1 (en) * | 2003-05-09 | 2016-07-27 | Novozymes A/S | Variant lipolytic enzymes |
| US20060236414A1 (en) | 2003-06-19 | 2006-10-19 | Novozymes A/S | Proteases and methods for producing them |
| EP1639102A2 (en) * | 2003-06-19 | 2006-03-29 | Novozymes A/S | Phospholipase variants |
| AR047440A1 (es) | 2004-01-21 | 2006-01-18 | Novozymes As | Produccion de un anticuerpo monoclonal en un hongo heterocarion o una celula huesped fungal |
| JP5032300B2 (ja) | 2004-03-22 | 2012-09-26 | アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 界面活性剤を含有している、リパーゼを含有する生成物の、とりわけパンクレアチンの経口医薬組成物 |
| DK1809320T3 (da) | 2004-10-14 | 2010-11-15 | Cystic Fibrosis Foundation The | Præparater indeholdende lipase, protease og amylase til behandling af pankreatisk insufficiens |
| US20080138856A1 (en) | 2005-02-10 | 2008-06-12 | Novozymes A/S | Enzymatic Enantioselective Ester or Amide Hydrolysis or Synthesis |
| KR20080017025A (ko) * | 2005-06-24 | 2008-02-25 | 노보자임스 에이/에스 | 약학적 용도의 리파제 |
| MX2007015471A (es) | 2005-06-24 | 2008-04-04 | Novozymes As | Amilasas para uso farmaceutico. |
| JP2008546395A (ja) | 2005-06-24 | 2008-12-25 | ノボザイムス アクティーゼルスカブ | 医薬使用のためのプロテアーゼ |
| WO2007080197A2 (en) * | 2006-01-16 | 2007-07-19 | Novozymes A/S | Immobilised enzymes |
| CN105296445B (zh) * | 2006-01-23 | 2022-05-10 | 诺维信公司 | 脂肪酶变体 |
| CA2635927A1 (en) * | 2006-01-23 | 2007-08-02 | The Procter And Gamble Company | A composition comprising a lipase and a bleach catalyst |
| WO2008079685A2 (en) * | 2006-12-21 | 2008-07-03 | Novozymes A/S | Lipase variants for pharmaceutical use |
-
2007
- 2007-12-12 WO PCT/US2007/087168 patent/WO2008079685A2/en not_active Ceased
- 2007-12-12 EP EP12155317.6A patent/EP2455461B1/en active Active
- 2007-12-12 EP EP10172609.9A patent/EP2261328B1/en active Active
- 2007-12-12 CN CN201510504893.8A patent/CN105112386A/zh active Pending
- 2007-12-12 EP EP12155315A patent/EP2455460A3/en not_active Withdrawn
- 2007-12-12 MX MX2009006597A patent/MX2009006597A/es not_active Application Discontinuation
- 2007-12-12 JP JP2009543078A patent/JP5406040B2/ja active Active
- 2007-12-12 BR BRPI0721103-1A patent/BRPI0721103A2/pt not_active IP Right Cessation
- 2007-12-12 CA CA2961041A patent/CA2961041C/en active Active
- 2007-12-12 CA CA2670643A patent/CA2670643C/en active Active
- 2007-12-12 US US12/519,868 patent/US8273348B2/en active Active
- 2007-12-12 KR KR1020097014850A patent/KR20090101930A/ko not_active Withdrawn
- 2007-12-12 EP EP07869130A patent/EP2099907A2/en not_active Withdrawn
- 2007-12-12 EP EP12155294.7A patent/EP2455459B1/en active Active
- 2007-12-12 EP EP12155319.2A patent/EP2455462B1/en active Active
- 2007-12-12 CN CN200780051638.6A patent/CN101743308B/zh active Active
- 2007-12-12 CA CA3081308A patent/CA3081308C/en active Active
- 2007-12-12 RU RU2009128067/10A patent/RU2009128067A/ru not_active Application Discontinuation
- 2007-12-12 AU AU2007337150A patent/AU2007337150A1/en not_active Abandoned
- 2007-12-18 TW TW096148377A patent/TW200829698A/zh unknown
- 2007-12-21 AR ARP070105859A patent/AR064494A1/es not_active Application Discontinuation
-
2009
- 2009-05-21 IL IL198893A patent/IL198893A0/en unknown
- 2009-05-25 ZA ZA200903598A patent/ZA200903598B/xx unknown
- 2009-07-20 NO NO20092729A patent/NO20092729L/no not_active Application Discontinuation
-
2012
- 2012-08-16 US US13/587,043 patent/US9029115B2/en active Active
-
2015
- 2015-04-06 US US14/679,563 patent/US9539311B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2961041C (en) | Lipase variants for pharmaceutical use | |
| US20090047266A1 (en) | Lipases for Pharmaceutical Use | |
| US8455235B2 (en) | Protease variants for pharmaceutical use | |
| AU2013203500B2 (en) | Lipase variants for pharmaceutical use | |
| AU2013200626B2 (en) | Lipase variants for pharmaceutical use | |
| HK1141553A (en) | Lipase variants for pharmaceutical use | |
| HK1145697A (en) | Protease variants for pharmaceutical use | |
| HK1113174A (en) | Lipases for pharmaceutical use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170314 |